VEGF levels in CSF and serum in mild ALS patients

Gao, Lina; Zhou, Shaodan; Cai, Haowei; Gong, Zhongying; Zang, Dawei

doi:10.1016/j.jns.2014.08.031

Cited by 26 publications

(15 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We previously reported that several cytokines are elevated in the CSF and serum of ALS patients (Gao, Zhou, Cai, Gong, & Zang, 2014; Gong, Gao, Guo, Lu, & Zang, 2015; Liu, Gao, & Zang, 2015; Yang, Gao, Wu, Zhang, & Zang, 2016). Here we expand on our earlier results by measuring a panel of factors in the CSF and serum from a larger group of ALS patients to intuitively and comprehensively show the differences in the factor levels between ALS patients and control subjects.…”

Section: Introductionmentioning

confidence: 99%

Evaluating the levels of CSF and serum factors in ALS

et al. 2017

Self Cite

View full text Add to dashboard Cite

ObjectivesThe aim of this study was to identify CSF and serum factors as biomarkers that may aid in distinguishing ALS patients from control subjects and predicting ALS progression as well as prognosis.MethodsSerum and CSF samples from 105 patients with ALS and 56 control subjects were analyzed for 13 factors using ELISA. The revised ALS functional rating scale (ALSFRS‐r) was used to evaluate the overall functional status of ALS patients, and we also followed up with ALS patients either by phone or with clinic visits for five years after enrollment in this study. Finally, we examined the correlations between factor levels and various clinical parameters and evaluated the predictive value for prognosis through a multivariate statistic model.ResultsA total of eight factors were obviously elevated in CSF, and twelve markers were increased in serum. In the correlation analyses, there were trends toward higher bFGF, VEGF, MIP‐1α levels in ALS with a longer disease duration and slower disease progression in both CSF and serum. Higher MCP‐1 levels were associated with worse disease severity and faster progression, and the IFN‐γ levels were positively associated with disease progression in either CSF or serum. Finally, a better prognosis was observed with higher levels bFGF in CSF and VEGF in CSF and serum; conversely, patients with higher levels of IFN‐γ in the CSF had shorter overall survival.ConclusionsWe demonstrated that a factor profile of ALS patients is distinct from control subjects and may be useful in clinical practice and therapeutic trials.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluating the levels of CSF and serum factors in ALS

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…In particular, the studies of cytokines and chemokines have developed rapidly. A number of ALS‐related factors, such as bFGF , VEGF , and MCP‐1 , might be considered to play critical roles in certain stages of ALS.…”

Section: Introductionmentioning

confidence: 99%

Increased levels of MIP-1αin CSF and serum of ALS

Yang

Gao

et al. 2015

Acta Neurol Scand

View full text Add to dashboard Cite

show abstract

“…Altered VEGF levels in the serum, CSF and anterior horn cells of ALS patients, and also in the spinal cord of mSOD1 mice, have been reported ( Brockington et al, 2006 ; Gao et al, 2014 ; Gupta et al, 2011 ; Lunn et al, 2009 ). Moreover, therapeutic potential of VEGF is shown using rodent models by retrograde delivery and by exogenous supplementation to NSC-34 motor neurons ( Azzouz et al, 2004 ; Krakora et al, 2013 ; Kulshreshtha et al, 2011 ; Vijayalakshmi et al, 2015 ).…”

Section: Discussionmentioning

confidence: 98%

Sporadic amyotrophic lateral sclerosis (SALS) – skeletal muscle response to cerebrospinal fluid from SALS patients in a rat model

Shanmukha

Gayathri

Nalini

et al. 2018

Disease Models &Amp; Mechanisms

View full text Add to dashboard Cite

Skeletal muscle atrophy is the most prominent feature of amyotrophic lateral sclerosis (ALS), an adult-onset neurodegenerative disease of motor neurons. However, the contribution of skeletal muscle to disease progression remains elusive. Our previous studies have shown that intrathecal injection of cerebrospinal fluid from sporadic ALS patients (ALS-CSF) induces several degenerative changes in motor neurons and glia of neonatal rats. Here, we describe various pathologic events in the rat extensor digitorum longus muscle following intrathecal injection of ALS-CSF. Adenosine triphosphatase staining and electron microscopic (EM) analysis revealed significant atrophy and grouping of type 2 fibres in ALS-CSF-injected rats. Profound neuromuscular junction (NMJ) damage, such as fragmentation accompanied by denervation, were revealed by α-bungarotoxin immunostaining. Altered expression of key NMJ proteins, rapsyn and calpain, was also observed by immunoblotting. In addition, EM analysis showed sarcolemmal folding, Z-line streaming, structural alterations of mitochondria and dilated sarcoplasmic reticulum. The expression of trophic factors was affected, with significant downregulation of vascular endothelial growth factor (VEGF), marginal reduction in insulin-like growth factor-1 (IGF-1), and upregulation of brain-derived neurotrophic factor (BDNF) and glial-derived neurotrophic factor (GDNF). However, motor neurons might be unable to harness the enhanced levels of BDNF and GDNF, owing to impaired NMJs. We propose that ALS-CSF triggers motor neuronal degeneration, resulting in pathological changes in the skeletal muscle. Muscle damage further aggravates the motor neuronal pathology, because of the interdependency between them. This sets in a vicious cycle, leading to rapid and progressive loss of motor neurons, which could explain the relentless course of ALS.This article has an associated First Person interview with the first author of the paper.

show abstract

VEGF levels in CSF and serum in mild ALS patients

Cited by 26 publications

References 34 publications

Evaluating the levels of CSF and serum factors in ALS

Evaluating the levels of CSF and serum factors in ALS

Increased levels of MIP-1αin CSF and serum of ALS

Sporadic amyotrophic lateral sclerosis (SALS) – skeletal muscle response to cerebrospinal fluid from SALS patients in a rat model

Contact Info

Product

Resources

About